Purpose: To assess the effects of monthly intravitreal ranibizumab injections in patients with vascularized pigment epithelium detachment (vPED) secondary to age-related macular degeneration (AMD). Methods: A total of 40 patients were prospectively observed and treated monthly with 0.5 mg ranibizumab injections (ClinicalTrials.gov Ident. NCT00976222). Inclusion criterion was a treatment-na€ ıve vPED lesion with a minimum height of ≥200 lm. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) were evaluated at all visits. Fluorescein angiography and indocyanine green angiography were performed at baseline and quarterly. Lesions were differentiated between serous vascular PED (svPED, group A, 29 patients) and fibrovascular PED (fPED, group B, 11 patients). Primary outcome was the effectivity of continuous monthly treatment during a 12-month period as measured in change in BCVA. Secondary outcomes were change in PED height and PED greatest linear diameter (GLD). Further secondary outcomes were the presence of subretinal fluid and prognostic markers of an impending retinal pigment epithelium (RPE) tear: PED lesion height and diameter, ratio of choroidal neovascularization (CNV) size to PED size, hyperreflective lines in near-infrared images, microrips and subretinal cleft. Results: Mean BCVA was 56.9 AE 11.5 letters (A: 55.4 AE 10.8; B: 59.1 AE 13.4) at baseline and 55.1 AE 15.9 (A: 53.7 AE 17.0; B: 58.9 AE 12.7) at 12-month follow-up. Excluding the RPE tear patients, the svPED group showed an increase in BCVA from 56.1 AE 10.3 at baseline to 62.4 AE 10.2 at 12-month follow-up (p = 0.048). Best-corrected visual acuity in patient who developed a RPE tear was 55.8 AE 12.5 at baseline and 37.1 AE 14.9 at 12-month follow-up. The mean change in PED height was À242.1 lm AE 285.5 (A: À427.3 lm AE 299.7; B: À51.6 lm AE 99.5). The mean decrease in PED GLD was À471.8 lm AE 727.6 (A: À738.9 lm AE 788.2; B: À10.4 lm AE 185.6). In group A, 10 patients developed a RPE tear (25%) after a mean of 3.6 injections. No tear was documented in group B. Lesion height, ratio of CNV size to PED size and presence of hyperreflective lines differed significantly between patients with and without RPE tear development. Conclusion: Serous vascular PED lesions showed an improvement regarding BCVA and morphologic characteristics unless an RPE tear occurred. In fPED lesions, a functional and morphological stabilization was observed. Monthly ranibizumab injections are an effective treatment regarding the resorption of subretinal fluid in vPED due to AMD. Patients should be screened for the presence of morphologic risk factors for RPE tear development before and during treatment.
Introduction
Intravitreal antivascular endothelial growth factor (VEGF) therapy has become an established treatment for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). In about 10 per cent of all patients, neovascular AMD is associated with a vascularized pigment epithelium detachment (vPED) (Pauleikhoff et al. 2002; Lommatzsch et al. 2009 ).
Large-scale multicentre studies, such as CATT and IVAN, showed that monthly anti-VEGF injections in neovascular AMD patients result in better functional results compared to a prore-nata regimen (Chakravarthy et al. 2012; Martin et al. 2012) . However, those trials do not finally answer the question whether AMD patients with vPED lesions functionally benefit from monthly anti-VEGF injections. In anti-VEGF treatment of vPED due to AMD, there is an additional safety aspect as some of the vPED lesions may develop tears of the retinal pigment epithelium (RPE) layer during treatment. A study by Sarraf and coworkers showed that the incidence of RPE tears increases in vPED patients treated with 2.0 mg ranibizumab compared to 0.5 mg (Sarraf et al. 2013) . A higher quantity of anti-VEGF seems to critically increase the contraction of CNV membranes under the surface of the vPED and eventually determines the RPE tear rate in patients at risk. So far, little information exists concerning the rate of RPE tear development in vPED patients under monthly injections, and it remains unclear whether potentially functional benefits of such a regimen outweigh the risk of RPE tear development or vice versa. Several prognostic markers for an impending RPE tear have been described such as vPED lesion height and diameter, hyperreflective lines in near-infrared images, a small ratio of CNV size to PED size, subretinal clefts, microrips and duration of vPED (Ie et al. 1992; Chan et al. 2007 Chan et al. , 2010 Chiang et al. 2008; Leitritz et al. 2008; Sarraf et al. 2010; Clemens et al. 2014 Clemens et al. , 2015 Doguizi & Ozdek 2014; Mukai et al. 2014) .
The aim of our study was to prospectively assess the effects of monthly intravitreal ranibizumab injections in patients with vPED secondary to AMD.
Patients and Methods
This study was conducted as a prospective, single-arm, interventional, multicentre study at the Departments of Ophthalmology at the Universities of Muenster, Bonn and Munich, Germany, between 2009 and 2014 (ClinicalTrials.gov Ident. NCT00976222) . Institutional review board approval was obtained prior to study procedures. Informed consent was obtained from each included study patient. All procedures adhered to the tenets of the Declaration of Helsinki.
Inclusion criteria were a treatmentna€ ıve vPED lesion associated with CNV due to neovascular AMD and a best-corrected visual acuity (BCVA) of 24-73 letters according to the Early Treatment Diabetic Retinopathy Study (ETDRS) score. Minimum vPED lesion height required for inclusion was ≥200 lm measured from Bruch's membrane to the RPE reference in spectral-domain optical coherence tomography (SD-OCT). Exclusion criteria included prior anti-VEGF therapy, subretinal haemorrhage, geographic atrophy, fibrovascular scar, pre-existing tear of the RPE, polypoidal choroidal vasculopathy or any other retinal disease.
Patients were treated monthly with intravitreal 0.5 mg ranibizumab. Primary outcome was the effectivity of continuous monthly treatment during a 12-month period as measured in change in BCVA. Secondary outcomes were change in PED height and PED greatest linear diameter (GLD) under the treatment regimen. Further secondary outcomes were the presence of subretinal fluid and prognostic markers of an impending RPE tear: PED lesion height and diameter, ratio of CNV size to PED size, hyperreflective lines in near-infrared images, microrips and subretinal cleft.
At baseline, patients underwent clinical examination including BCVA using ETDRS charts, SD-OCT (OCT Scan Pattern: 61 B-scans, 30°9 25°, distance between B-scans: 119 lm), fluorescein angiography (FA) and indocyanine green angiography (ICGA) (30°9 30°, 768 9 768 pixel) (Spectralis; Heidelberg Engineering, Heidelberg, Germany). During follow-up, BCVA and SD-OCT (except first and third visit) were evaluated at all visits. Fluorescein angiography and ICGA were performed at baseline and quarterly.
Pigment epithelium detachment height was measured as the vertical distance from Bruch's membrane to the RPE border using the OCT scan revealing the most prominent lesion site. Pigment epithelium detachment GLD was measured in the scan showing the maximum horizontal PED diameter and was measured as the maximum distance from RPE elevation to RPE elevation.
The classification of serous vascularized PED versus fibrovascular PED (fPED), the presence of subretinal fluid as well as the following prognostic markers of an impending RPE tear were assessed retrospectively: (i) PED lesion height, (ii) PED lesion diameter, (iii) ratio of CNV size to PED size, (iv) hyperreflective lines in near-infrared images, (v) microrips, (vi) subretinal cleft.
vPED lesion types
Based on SD-OCT, FA and ICGA, vPED lesions were identified and classified into two forms: Group A: serous vascularized PED (svPED) identified by the presence of shading background fluorescence in the area of the PED in the early phase, followed by gradual appearance of a circular zone of intensifying and irregular hyperfluorescent leakage at the margin of the PED corresponding to the CNV. Spectral-domain optical coherence tomography (SD-OCT) scans show hyperreflective structures underneath the RPE that represent the CNV and fill out only part of the PED cavity (Clemens & Eter 2016) . Group B: fibrovascular PED with underlying occult CNV identified by areas of stippled hyperfluorescence and signs of leakage in the later phases (MPS Group 1996) . In SD-OCT scans, the PED lesion's cavity appears to be completely filled out by the CNV membrane (Clemens & Eter 2016) .
Statistical methods
Data were analysed for the entire patient group, the svPED group, the fPED group, the group of patients who developed an RPE tear and the group of patients who developed no RPE tear. Best-corrected visual acuity data were calculated by Wilcoxon matched-pairs signed rank test. Morphological data were calculated by Mann-Whitney U-test. Statistical significance was set at p < 0.05.
Results
Forty patients completed the study protocol. Mean age was 73.4 AE 5.4 years, and 23 patients were female. The mean number of injections per patient was 11.3. Twenty-nine patients revealed criteria of a svPED, and 11 patients showed typical characteristics of a fPED. Mean BCVA was 56.9 AE 11.5 EDTRS letters (A: 55.4 AE 10.8; B: 59.1 AE 13.4) at baseline and 55.1 AE 15.9 EDTRS letters (A: 53.7 AE 17.0; B: 58.9 AE 12.7) at 12-month follow-up (p = 0.656; A: p = 0.689; B: p = 0.813; Fig. 1 ).
Mean BCVA in the patient group who developed a RPE tear (n = 10) during the follow-up period was 55.8 AE 12.5 at baseline and 37.1 AE 14.9 at 12-month follow-up (p = 0.003) compared to those patients without RPE tear development (n = 30) that showed a BCVA of 57.2 AE 11.4 at baseline and 61.1 AE 11.1 at 12-month follow-up (p = 0.157), respectively. Excluding the RPE tear patients, the svPED group showed a distinct increase in visual acuity from 56.1 AE 10.3 at baseline to 62.4 AE 10.2 at 12-month followup (p = 0.048).
Mean PED height significantly decreased from 565.4 lm AE 305.1 at baseline to 437.4 lm AE 232.7 after 3 months, 369.7 lm AE 184.3 after 6 months and 323.3 lm AE 187.1 after 12 months of treatment. The mean decrease after 12 months was À242.1 lm AE 285.5 (p ≤ 0.01). In group A, mean PED height decreased from 733.8 lm AE 347.5 at baseline to 469.2 lm AE 283.1 at 3 months, 380.7 lm AE 237.0 at 6 months and to 306.5 lm AE 215.6 at 12 months after treatment resulting in a significant difference compared with the baseline value (À427.3 lm AE 299.7; p ≤ 0.01).
The baseline values for group B were 403.9 lm AE 154.9, and the Subanalysis of the patients who developed an RPE tear showed a lesion height at baseline of 876.2 lm AE 332.6 (n = 10) compared to 565.4 lm AE 305.1 in the no-tear group (n = 30) (p = 0.01). In the RPE tear group, 60% of patients showed no subretinal fluid after two injections. In group A, 10 patients developed a RPE tear (25%) after a mean of 3.6 injections. No tear was documented in group B.
Retrospective evaluation of previously described RPE tear risk factors revealed the following results: hyperreflective lines were present in 32.5% of all patients (RPE tear group: 70%; no RPE tear group: 19.4%; p = 0.006). Pigment epithelium detachment lesion diameter was 2767.7 lm AE 1276.4 in the RPE tear group (no RPE tear group: 2616.7 lm AE 1060.5; p = 0.20). The ratio of CNV size to PED size was 0.49 in all patients (RPE tear group: 0.27; no RPE tear group: 0.56; p = 0.013). A microrip was observed in one patient. A subretinal cleft was observed in eleven patients (RPE tear group: two patients; no RPE tear group: nine patients; p = 0.696). Figure 3 shows data of prognostic markers of an impending RPE tear.
Discussion
Large-scale multicentre studies, such as MARINA and ANCHOR, showed a significant increase in visual acuity of 7.2 and 11.3 letters after 12 months of monthly treatment with 0.5 mg ranibizumab Rosenfeld et al. 2006) . However, patients suffering from a vPED due to AMD were not included in these studies. Similarly, the multicentre HARBOR study included only patients with a total CNV area constituting 50% or more of total lesion area based on FA, which excludes particularly those vPED lesions that have a high risk of RPE tear development (Ho et al. 2014) .
Interestingly, our data reveal that gains in visual acuity as previously reported could not be achieved in all of our vPED patients (Schmidt-Erfurth et al. 2015) . Visual acuity (VA) of patients suffering from a fPED was stabilized under monthly treatment, while vision was distinctly improved in svPED patients unless a tear of the RPE occurred during treatment regimen.
Presumably, the functional difference is attributable to the greater anatomic improvement in svPED lesions. Both lesion height and lesion GLD decreased more in svPED patients compared to fPED patients. However, this observation is certainly biased by patients who developed a RPE tear, which occurred exclusively in the svPED group. The development of a RPE tear usually results in a significant flattening of the lesion. Therefore, it is worth looking at the data of PED height as subgroups svPED with RPE tear and without RPE tear.
Serous vascularized PED lesions appear to have a higher mechanical potential for PED resolution than fPED. The underlying neovascular membrane may be a mechanical obstacle for lesion flattening in fPED. Correspondingly, a complete lesion flattening only occurred in the svPED group in 30% of patients, which is in accordance with previous data. Similarly, a complete absorption of subretinal fluid after three injections in approximately 70% is in accordance with previously published data (Schmidt-Erfurth et al. 2015). The decrease in PED height was most significant between the first and the second injections, which is in accordance with previous studies (Wolf et al. 2013; Chan et al. 2015) . Our data indicate that there is a variable response to treatment, whereas overall there was a significant reduction in PED height. Compared to previous studies using a pro-re-nata regimen in vPED patients, the change in BCVA and lesion height appears similar after a 12-month treatment (Inoue et al. 2013) .
One downside of fixed monthly injections is the potential development of macular atrophy. An acceleration or progression of macular atrophy caused by anti-VEGF treatment has recently become a subject of debate. Munk et al. (2016) analysed a large group of patients under long-term anti-VEGF therapy and found macular atrophy in a majority of patients.
Whether a monthly treatment regimen in vPED patients proves to be beneficial appears questionable with regard to the presumed pathophysiology of RPE tear development under anti-VEGF therapy. Since the beginning of the anti-VEGF era, an increase in the RPE tear incidence in AMD patients has been observed which was interpreted as a confirmation of the established theory of tractional forces causing the tear event (Gass 1984; Chuang & Bird 1988; Toth et al. 1995; Lafaut et al. 2001) . Antivascular endothelial growth factor (VEGF) agents cause an increase in contraction of CNV membranes adherent to the undersurface of the RPE inducing shrinkage of the RPE, which causes an increased tension on the surface of the vPED cavity and eventually results in the anatomic failure of the RPE at the junction of attached and detached RPE. Based on these observations, one may hypothesize that the higher the quantity of anti-VEGF injected intravitreally, the higher the contraction of the CNV membrane and the stronger the traction forces acting on the RPE.
Data from our study reveal a fairly high number of RPE tears in comparison with previous prospective vPED studies that used a pro-re-nata treatment scheme. An obvious explanation may be that monthly injections result in a certain anti-VEGF quantity that exceeds a critical threshold in such high-risk patients. A study by Sarraf and co-workers supports this notion. They prospectively treated patients with vPED with different dosages of ranibizumab, and interestingly, they found that 80% of RPE tears occurred in the high-dose 2.0-mg group suggesting that this high-dosage regimen also leads to intravitreal anti-VEGF quantities above a critical threshold (Sarraf et al. 2013) .
The higher number of RPE tears found in our prospective study could also be due to a higher risk profile of our patients treated. Notably, there is no clear consensus of risk factors for lesions developing an RPE tear. Retinal pigment epithelium tears in our study occurred exclusively in the group of svPED lesions, and no RPE tear developed in the fPED group. The mechanical proportions in these two vPED types presumably explain this clear-cut difference. In fPED, the lesion cavity is entirely filled by the CNV membrane. Therefore, contraction forces in response to anti-VEGF therapy may spread evenly over the entire PED lesion exposing the RPE monolayer to bearable mechanical stress, whereas in svPED, the mechanical situation is comparably unfavourable as the lesion is for the most part filled by a fluid bleb and only partly filled out by the CNV.
The large multicentre studies in neovascular AMD showed that the biggest change in retinal thickness occurs after the first treatment, which suggests that the first anti-VEGF injection has the largest morphological impact on the retina and stresses the RPE the most (Chakravarthy et al. 2012; Martin et al. 2012) . In accordance with previous studies, most RPE tears in our study occur during the first three injections (Wolf et al. 2013; Doguizi & Ozdek 2014) . However, in a minor part of three patients, RPE tears developed later after the first three injections when, interestingly, subretinal fluid had already been resorbed. If treatment in those patients had been paused after the complete resorption of subretinal fluid, those RPE tears may have been prevented. If subretinal fluid is completely resorbed, the lesion should be regarded as inactive and anti-VEGF treatment should be paused (Schmidt-Erfurth et al. 2014) . The aim of the intravitreal treatment is not to achieve a maximum flattening of the vPED lesion rather than to assure a total absence of subretinal fluid. Aiming at an excessive flattening of the vPED lesion in the absence of subretinal fluid unnecessarily increases the risk of an RPE tear without any functional benefits.
The fact that subretinal fluid is often already resorbed after the first injection and that most RPE tears occur during the first three injections may suggest that one should consider a pro-re-nata regimen with careful observation particularly during the first injection in high-risk PED patients. Notably, a complete resorption of subretinal fluid after the very first injection should be interpreted as a strong response to anti-VEGF going along with a high degree of mechanical stress on the RPE.
The analysis of RPE tear risk factors in the literature shows that three parameters are important to look at: PED height, PED diameter and CNV/ PED ratio. Pigment epithelium detachment height in RPE tear patients in our study was 876.2 lm, which is in accordance with that of Doguizi et al. who calculated a PED height of 580 lm above which this parameter represents a significant risk factor for tear development (Doguizi & Ozdek 2014) . Similarly, Sarraf et al. described a height of 550 lm as a high-risk factor for the subsequent development of an RPE tear, and additionally, Leitritz and coworkers described an increasing probability of RPE tears particularly beyond the height of 400 lm (Leitritz et al. 2008; Sarraf et al. 2013 ).
Chan and colleagues reported that a lesion diameter of >1397 lm represents a significant risk factor for RPE tear development (Chan et al. 2010) . Comparably, our patients showed a lesion diameter of 2767.7 lm in the RPE tear group. Chan et al. firstly described the concept of a CNV/PED ratio representing another crucial risk factor for tear development (Chan et al. 2007) . Our data support this notion as RPE tear patients showed a significantly smaller CNV/PED ratio compared to non-RPE tear patients.
In accordance with previous reports, our analysis revealed clear data that confirm hyperreflective lines in infrared images as a predictive factor (Clemens et al. 2014 ). This factor is not present in all RPE tear patients. Possibly, hyperreflective lines in the infrared modality exist only for a short period of time prior to the RPE tear event, and therefore, this phenomenon may well occur in between study visits and may not always be detected. Secondly, a certain amount of traction must be present to form the folds in the RPE that correspond to the hyperreflective lines in infrared images. Certain patients may have a poorly resistant RPE monolayer so that already a small amount of traction is sufficient to cause a tear while being insufficient to make this phenotype appear. The parameters subretinal cleft and microrip do not show a significant correlation to RPE tear development. The relevance of these two criteria remains unclear as they have only been described in case series so far. Their incidence seems to be low. Nevertheless, their sensitivity to predict an RPE tear development should be further addressed in future studies.
The study is limited by several factors. Despite the high rate of RPE tears, the absolute number remains obviously small. However, a prospective study on RPE tear development in vPED remains a challenge as it requires a large number of included patients as well as a huge amount of study centre infrastructure. Nevertheless, a future prospective study with a higher number of patients developing an RPE tear is necessary to firstly verify each potential risk factor and secondly to stratify the weight of each risk factor. This way it would be possible to quantify the risk of an RPE tear development of each individual vPED patient undergoing anti-VEGF therapy. In this study, the analysis of subretinal fluid and predictive factors was performed retrospectively.
In conclusion, svPED lesions showed an improvement regarding BCVA and morphologic characteristics unless an RPE tear occurred. In fPED lesions, a functional and morphological stabilization was observed. Monthly ranibizumab injections are an effective treatment regarding the resorption of subretinal fluid in vPED due to AMD. The fact that subretinal fluid is often already resorbed after the first injection and that most RPE tears occur during the first three injections may suggest that one should consider a pro-re-nata regimen with careful observation particularly during the first injection in high-risk vPED patients. In addition, patients should be screened for the presence of morphologic risk factors for RPE tear development before and during treatment.
